金属硫蛋白与肿瘤增殖抗原在卵巢上皮性肿瘤组织中的表达及意义  

Expressions of metallothionein and tumor proliferating antigen in epithelial ovarian carcinoma tissues and their significances

作　　者：高迎春[1] 张爽[1] 

机构地区：[1]辽宁医学院附属第一医院,辽宁锦州121000

出　　处：《中国妇幼保健》2011年第6期907-908,共2页Maternal and Child Health Care of China

摘　　要：目的:研究金属硫蛋白(MT)和肿瘤增殖抗原(Ki-67)在卵巢上皮性肿瘤组织中的表达及相关性和临床意义。方法:采用免疫组化SP法及半定量分析法,检测105例卵巢上皮性肿瘤病理标本中的MT及Ki-67蛋白表达。结果:MT在卵巢癌及正常组织中表达有差异(P<0.01),Ki-67在不同组织学类型卵巢肿瘤间表达无明显差异(P>0.05);MT与Ki-67的表达强度恶性肿瘤高于正常、良性、交界性肿瘤(P<0.05),临床Ⅲ、Ⅳ期,病理2、3级的恶性肿瘤高于临床Ⅰ、Ⅱ期,病理1级者(P<0.01);MT与Ki-67的表达强度在恶性上皮性卵巢肿瘤中有显著相关性(P<0.05)。结论:组织中MT、Ki-67的表达强度与卵巢肿瘤的性质有关,MT和Ki-67可能作为卵巢肿瘤的预后预测参考指标。Objective：To study the expressions of metallothionein and tumor proliferating antigen（Ki-67） in epithelial ovarian carcinoma tissues,analyze their correlation and clinical significances.Methods：Immunohistochemical SP method and semi-quantitative analysis were used to detect the expressions of metallothionein and Ki-67 protein in pathological samples of epithelial ovarian carcinoma.Results：There was significant difference in expression level of metallothionein between ovarian cancer and normal ovary（P〈0.01）,there was no significant difference in expression level of Ki-67 protein among ovarian carcinoma of different histological types（P〉0.05）;the expression levels of metallothionein and Ki-67 protein in malignant tumors were significantly higher than those in normal ovary,benign and borderline tumors（P〈0.05）;the expression levels of metallothionein and Ki-67 protein in malignant tumors of clinical stage Ⅲ,Ⅳ,pathological grade 2,3 were significantly higher than those in malignant tumors of clinical stage Ⅰ,Ⅱ,pathological grade 1;in malignant epithelial ovarian tumors,there was a significant correlation between metallothionein expression and Ki-67 protein expression（P〈0.05）.Conclusion：The expression levels of metallothionein and Ki-67 protein are related to tumor type,metallothionein and Ki-67 protein may be used as indications of clinical prognosis of ovarian tumors

关 键 词：卵巢癌 金属硫蛋白 肿瘤增殖抗原 

分 类 号：R737.31[医药卫生—肿瘤]